Kymera is at the forefront of a new technology called targeted protein degradation that offers us a new way to treat disease.
Targeted Protein Degrader Medicines Work with Your Cells to Fight Disease
Targeted protein degradation (TPD) harnesses the natural process your cells use to keep themselves healthy by identifying and tagging misshapen or old proteins and directing them toward the cell’s built-in recycling system. Our medicines are designed to work with this system to selectively remove proteins that cause disease, with the goal of creating more effective medicines.
Clinical Trials
Clinical trials advance disease treatment by testing the safety and efficacy of the investigational medicines we are developing. Talk to your physician about whether a clinical trial or novel treatment is right for you and discover more about our ongoing trials below.
KT-474 (SAR444656) is an investigational degrader in development for the treatment of immunological and inflammatory diseases
The safety and efficacy of KT-474 (SAR444656) is currently being evaluated in double blind, placebo-controlled, randomized Phase 2 clinical trials in adult patients with moderate to severe Hidradenitis Suppurativa and Atopic Dermatitis.
KT-253 is an investigational degrader in development for the treatment of solid tumors and hematological malignancies
This is an open-label Phase 1 first-in-human study of KT-253 in adult patients to evaluate safety, tolerability, pharmacokinetics/pharmacodynamics, and clinical activity in liquid and solid tumors.
KT-333 is an investigational degrader in development for the treatment of solid tumors and hematological malignancies
This is an open-label Phase 1 first-in-human study of KT-333 in adult patients to evaluate safety, tolerability, pharmacokinetics/pharmacodynamics, and clinical activity in liquid and solid tumors.
Kymera’s investigational drugs are currently at a stage in development where we are focused on enrolling patients in our clinical trials and continuing to learn more about our investigational drugs’ safety and efficacy. At this time, Kymera is not able to make expanded access available to its investigational drugs. For more information, please read our full expanded access policy.
Kymera is proud to partner with advocacy groups that represent and support patients and their families living with a specific condition.
As the leading source of free blood cancer information, education, and support for patients, survivors, families, and healthcare professionals, LLS helps patients navigate their cancer treatment and ensures they have access to quality, affordable, and coordinated care.